Akari Therapeutics, Plc
AKTXNASDAQHealthcare● Active
$15.45
+$0.38(+2.49%)
Market Cap$17678146
P/E Ratio—
52W High$54
52W Low$3.015
Akari Therapeutics, Plc (AKTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AKTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 19, 2026EPS Actual
-$1.33
Est. -$1.33 · +0.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 19, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
AKTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$1.39 | — | — | — | — | — |
| — Q2 FY2026 | May 19, 2026 | -$1.33 | -$1.33 | +0.0% | — | — | — |
| ▼ Q2 FY2026 | Apr 7, 2026 | -$1.80 | -$2.99 | -66.1% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.04 | -$0.10 | -150.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.09 | -$0.06 | +33.3% | — | — | — |
| — Q2 FY2025 | May 14, 2025 | — | -$0.14 | — | — | — | — |
| ▲ Q2 FY2025 | Apr 14, 2025 | -$1.00 | -$0.17 | +83.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 19, 2024 | -$0.60 | -$9.60 | -1500.0% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$1.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 19, 2026
EPS Actual
-$1.33
EPS Est.
-$1.33
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2026
Apr 7, 2026Miss
EPS Actual
-$2.99
EPS Est.
-$1.80
EPS Surpr.
-66.1%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.04
EPS Surpr.
-150.0%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.09
EPS Surpr.
+33.3%
Revenue
—
Q2 FY2025
May 14, 2025
EPS Actual
-$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 14, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$1.00
EPS Surpr.
+83.0%
Revenue
—
Q4 FY2024
Nov 19, 2024Miss
EPS Actual
-$9.60
EPS Est.
-$0.60
EPS Surpr.
-1500.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.26 | $-1.26 | $-1.26 | 1 |
| Q3 FY2027 | $-1.22 | $-1.22 | $-1.22 | 1 |
| Q2 FY2027 | $-1.12 | $-1.12 | $-1.12 | 1 |
| Q1 FY2027 | $-1.08 | $-1.08 | $-1.08 | 1 |
| Q4 FY2026 | $-1.56 | $-1.56 | $-1.56 | 1 |
| Q3 FY2026 | $-1.50 | $-1.50 | $-1.50 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 19, 2026 | +0.0% | $3.50 | $3.74 | +6.86% |
| ▼ Q2 FY2026 | Apr 7, 2026 | -66.1% | $3.54 | $3.80 | +7.34% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -150.0% | $21.72 | $20.80 | -4.24% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +33.3% | $40.80 | $39.30 | -3.68% |
| — Q2 FY2025 | May 14, 2025 | — | $56.00 | $54.00 | -3.57% |
| ▲ Q2 FY2025 | Apr 14, 2025 | +83.0% | $42.80 | $44.40 | +3.74% |
| ▼ Q4 FY2024 | Nov 19, 2024 | -1500.0% | $91.60 | $62.80 | -31.44% |
| ▼ Q3 FY2024 | Aug 19, 2024 | -220.0% | $136.80 | $144.00 | +5.26% |
Q2 FY2026+6.86%
Report Date
May 19, 2026
EPS Beat/Miss
+0.0%
Price Before
$3.50
Price After
$3.74
Q2 FY2026+7.34%
Report Date
Apr 7, 2026
EPS Beat/Miss
-66.1%
Price Before
$3.54
Price After
$3.80
Q4 FY2025-4.24%
Report Date
Nov 13, 2025
EPS Beat/Miss
-150.0%
Price Before
$21.72
Price After
$20.80
Q3 FY2025-3.68%
Report Date
Aug 13, 2025
EPS Beat/Miss
+33.3%
Price Before
$40.80
Price After
$39.30
Q2 FY2025-3.57%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$56.00
Price After
$54.00
Q2 FY2025+3.74%
Report Date
Apr 14, 2025
EPS Beat/Miss
+83.0%
Price Before
$42.80
Price After
$44.40
Q4 FY2024-31.44%
Report Date
Nov 19, 2024
EPS Beat/Miss
-1500.0%
Price Before
$91.60
Price After
$62.80
Q3 FY2024+5.26%
Report Date
Aug 19, 2024
EPS Beat/Miss
-220.0%
Price Before
$136.80
Price After
$144.00
Avg Beat Reaction+2.31%
Avg Miss Reaction-5.77%
Beat Rate3 / 8 quarters
Largest Move-31.44% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AKTX ends December
Akari Therapeutics, Plc (AKTX) most recently reported earnings on May 19, 2026 for Q2 FY2026, posting EPS of $-1.33 (in line with the analyst consensus of $-1.33). The next AKTX earnings date is expected around September 1, 2026.
Each quarter, investors track AKTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AKTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AKTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AKTX earnings · 4 questionsAkari Therapeutics, Plc's next earnings report is expected around September 1, 2026. AKTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AKTX historically reports after market close (AMC).
AKTX earnings datewhen is AKTX earningsAKTX next earnings datewhen does AKTX report earningsAKTX earnings calendar
▸ Source: FMP · Akari Therapeutics, Plc SEC filings · US GAAP · Akari Therapeutics, Plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026